Background: Seasonal influenza concerns the worldwide population every year, whilst
INTRODUCTION
In annual influenza epidemics, 5-15% of the world population is affected with acute respiratory infection. Most people with the illness recover quickly, but children, elderly and those with chronic medical conditions are at higher risk for complications and sometimes death (OECD, 2011) . According to the World Health Organization (WHO) these annual epidemics result in 3-5 million cases of severe illness and 250-500 thousand deaths worldwide. In terms of costs of healthcare, lost days of work and education, and social disruption are between USD 1 million and USD 6 million per 100,000 inhabitants yearly in industrialized countries (WHO, 2009 ). In the case of influenza pandemic, this impact could be increased by a high order of magnitude (Chick et al., 2008) .
Policy-makers at all levels are usually interested in the socioeconomic impact of influenza, in order to better allocate resources for strategies of prevention and control, such as vaccines (Jefferson and Demicheli, 1998) . Although vaccines could be considered effective (Germann et al., 2006; Osterholm et al., 2012) and cost-effective (Nichol et al., 1994) , their suboptimal allocations can be attributed to misaligned incentives of policy-makers (Chick et al., 2008) .
Nevertheless, there is a lack of studies evaluating the decision-making process regarding the supply chain of vaccines and vaccination strategies during seasonal or pandemic contexts.
This situation leads to the main question of our research: which kind of evidence do policymakers use when facing decisions concerning influenza?
The objective of this literature review is to emerge studies evaluating the decision-making process related to the influenza vaccination policy. The secondary objectives are to identify the actors involved and their role in the process, to describe the information used in decision making for vaccination policy, to group by type of information, to classify by level of importance, to describe the decisions made. halshs-00808536, version 1 -5 Apr 2013
METHODS

Search definitions
Keywords were chosen based on the terms of the Medical Subject Heading (MeSH). They were combined according to the main objective of this literature review: study the decision making process of influenza vaccination policy: -Cochrane (collection of databases in medicine and other healthcare specialties; database of systematic reviews and meta-analyses, which summarize and interpret the results of medical research)
References without abstracts and which full text was written in other language different from English, French, Spanish, German, Italian and Portuguese were excluded.
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Specific databases such as the Centers for Disease Control and Prevention's (CDC) reports or the World Health Organization (WHO) Bulletins were also searched.
Criteria for inclusion and exclusion
The articles retrieved had titles and abstracts screening according to criteria of inclusion and exclusion established.
Inclusion criteria -Presence of macro 1 level decision-making (at local, regional, national or international levels) regarding influenza vaccination programs (target groups, reimbursement…) and vaccines (formulation, stockpile, distribution, production, management…),
-Description of the actors involved in this decision,
-Description of the information used during the decision making process assessed.
Exclusion criteria
-Decisions made in meso or micro 2 levels only, such as in hospitals, clinics or medical offices (relation between physicians and patients),
-Assessments of the willingness of people (general population, health care professionals, parents of children…) to get vaccinated or to accept recommendations or requirements about getting vaccinated, -Modeling studies concerning past vaccination strategies adopted, or proposition of new strategies (optimal vaccination strategies),
-Economic evaluations (cost-benefit, cost-effectiveness, cost-of-illness, economic burden…) about vaccine efficacy/effectiveness and vaccination rate.
Checklist for full text reading
Articles selected to full text reading were checked according to the following list:
-What is the current context (influenza pandemic or seasonal, health system, politics, socio-demographic, economics)?
-Which decisions are under discussion (vaccination strategies and vaccines)?
1 From an organization perspective, the macro level refers to the actors and institutions within which the general organizational, regulatory frameworks and public health interventions of the broad health system are established and delivered, beyond national borders or not.
2 From an organization perspective, the meso level refers to medium-sized units of service provision such as primary healthcare units or hospitals, and the micro level refers to interactions between individual patients and healthcare professionals. Aiming to facilitate the analysis we classified each of the points highlighted in the checklist.
This classification is based in the common characteristics of stakeholders and the impact of the information in the decision made.
RESULTS
Articles inclusion
Electronic databases search retrieved 4743 references. Based on the titles and abstracts, we excluded: 465 articles that did not have an abstract, 348 repeat texts and 3588 that did not meet the inclusion criteria. 342 articles were selected for full text reading. After a detailed reading of those, 231 (68%) were excluded because they actually didn't match the inclusion criteria. Finally, we consider for analysis 111 articles (Annex 1).
Most of the articles excluded concerned local decision-making process (meso/micro level). Representing the east side of the globe, Australia (n=7), India (n=2) and Hong Kong (n=1) evaluated their vaccination strategy and pandemic preparedness plan. Table 1 details the location where the studies were conducted.
3 The US government is responsible for the buying and distribution of influenza vaccines in the US. This work is largely carried out by the Centers for Disease Control and Prevention. As a result, there are many US publications in the public domain regarding this issue which appear every year. For example, the CDC gives a regular update on vaccine supplies each winter. However, this is not comparable to other countries where other procedures are at work and supply is often left more to the private market.
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Current context
In order to classify the articles found, we use the assumptions driven by the virus-centric thinking which leads to dichotomizing influenza into "pandemic" and "seasonal", according to the genetic mutations of the flu virus (Doshi, 2011) . On this basis, we found that 81 articles were related to pandemic and 24 to seasonal flu. Some articles (n=6) discussed how seasonal influenza surveillance systems could be used in pandemic situations, giving emphasis on both seasonal and pandemic contexts. Half of the 111 articles included, target the preparedness plan for influenza pandemic, before, during and after the occurrence of a pandemic. Ancient and recent pandemics (1918, 1957, 1968, 2009) 
Stakeholders
The noun "stakeholder" receives different definitions according to the environment in where it is used. In our research, we adopted the business concept retrieved at the Collins Dictionary online (Collins, 2012) which defines stakeholder as: "a person, group, organization, member or system that affects or can be affected by a project or event".
Stakeholder cans also be used as an adjective that matches with our study: "of or relating to policies intended to allow people to participate in and benefit from decisions made by enterprises which they have a stake". Stakeholders, related to influenza vaccination policy, who participate in and benefit from decisions made by health organizations which they have a stake were identified and classified in the following groups: o General public.
Information influencing decisions and other factors of impact
Main information and factors influencing decisions were identified in the articles selected.
Fourteen categories were established and ranked in Table 2 according to its impact on the decision.
halshs-00808536, version 1 -5 Apr 2013 , 4, 6, 8, 9, 10, 11, 13, 14, 16, 17, 20, 30, 33, 38, 39, 45, 50, 51, 53, 57, 58, 62, 63, 64, 68, 71, 72, 73, 74, 76, 77, 81, 83, 89, 91, 94, 97, 98, 103, 105, 107, 108, 114, 115, 125 Influenza surveillance data n=41
Flu activity Transmissibility Geographic distribution Time course of pandemic 6, 7, 8, 11, 13, 17, 20, 22, 23, 24, 26, 29, 32, 36, 37, 44, 51, 55, 56, 63, 66, 70, 71, 72, 73, 76, 82, 83, 84, 86, 90, 93, 97, 98, 107, 109, 113, 114, 115, 119, 126 Vaccines scientific studies n=37
Randomized clinical trials: vaccine efficacy effectiveness safety clinical evidence, scientific, observational studies immunization 1, 4, 11, 13, 14, 28, 30, 31, 32, 33, 34, 36, 37, 38, 44, 45, 46, 53, 56, 58, 59, 61, 67, 69, 73, 75, 78, 81, 85, 86, 93, 99, 100, 101, 102, 104, 105 Local status, social conditions n=26
Logistics for pandemic response Education Politics (political willingness) Economy Media Transparency 18, 28, 39, 41, 42, 44, 45, 50, 53, 54, 61, 80, 85, 87, 88, 89, 90, 91, 97, 99, 107, 113, 115, 117, 121, 125 Epidemiology n=25 Morbidity Mortality Severity 3, 8, 10, 11, 13, 15, 18, 23, 24, 30, 33, 36, 41, 49, 54, 56, 71, 73, 74, 81, 84, 92, 109, 115, 132 Ethics n=24
Professional judgments Cultural requirements Willingness to be vaccinated Legal/juridical approaches Philosophy grounds 5, 11, 16, 19, 42, 46, 48, 51, 58, 67, 69, 70, 76, 78, 81, 87, 89, 92, 93, 99, 101, 102, 103, 121 Guidelines n=24
Reviews, reports, records, publications, website docs Protocols, checklist Recommendation 3, 19, 25, 26, 30, 31, 34, 41, 47, 50, 54, 55, 58, 66, 68, 75, 85, 97, 102, 110, 111, 112, 124, 131 Virological diagnosis n=19 Serological Antigenic strains Laboratory capacity 6, 13, 23, 28, 29, 38, 44, 53, 57, 64, 66, 71, 93, 96, 100, 104, 114, 119, 126 halshs-00808536, version 1 -5 Apr 2013
Main information, number of articles related
Information detailed #
Financial resources n=18
Funding Budget 10, 14, 25, 29, 49, 51, 62, 64, 74, 77, 97, 98, 100, 101, 102, 104, 114, 119 Registries n=16
Past pandemic information History Lessons learned 8, 11, 12, 13, 15, 26, 60, 62, 63, 68, 86, 93, 99, 108, 110, 132 Models n=14
Mathematical Decision policy analysis 6, 7, 11, 12, 15, 16, 20, 24, 38, 51, 52, 96, 108, 109 Experts advices n=13 
Decisions made
Two main categories of decisions were established: (1) vaccination strategy and (2) pandemic preparedness plan. Vaccination strategy is analyzed in both pandemic and seasonal contexts.
Although vaccination strategy can be part of a pandemic preparedness plan, it is here analyzed separately (Annex 2). This final step will not be analyzed once it concerns a lower level of decision (patient level, social acceptance of getting vaccines), and we are interested in higher levels (policy level).
2) Pandemic Preparedness Plan (n=37, 28%) 6 Generally, when policy makers elaborate an influenza pandemic preparedness plan, a vaccination strategy is included as one of the measures for containing pandemic virus spread.
Other measures for control are also included in the plan, such as social distance and isolation 
Population target for vaccination
The first issue to be considered when planning for a seasonal or pandemic influenza is the target population for vaccination. This is based on assumptions of the group that might get most benefit from vaccination. Studies assessing vaccine effectiveness, economic evaluations, type of influenza epidemiology (morbi-mortality) and data about vaccination rates are useful to justify choices made (Lee et al., 2012; Lipsitch et al., 2011) .
Vaccines formulation and production
WHO recommends annually the virus composition of seasonal influenza vaccine for both northern and southern hemispheres. These recommendations are based on surveillance data from sentinel influenza networks worldwide and antigenic virological information provided during the whole year by the National Influenza Centres responsible for virus identification, subtyping and characterization. For pandemic vaccines, once the virus is isolated, recommendations about the antigenic characteristics are provided. Manufacturers have then some months before the winter season, where influenza is epidemic, to make available a sufficient amount of vaccines for supplying the world demand. Commercial interest associated with studies of vaccine effectiveness in different age groups and antigenic match (between the circulating virus and the current vaccine composition) encourage manufacturers to promote new types of vaccines. These vaccines can present different formulations from the ones recommended by WHO, target a specific age group, or can be available by nasal administration, for instance (Kamradt-Scott, 2012; Yaesoubi and Cohen, 2011) .
Communication
Communication between stakeholders involved in the decision making process was seen to be very important for the success of the vaccination policy. Collaboration between different levels of governance (federal, state/regional, local), health institutes, experts and halshs-00808536, version 1 -5 Apr 2013 manufacturers enable robustness of information produced and evidence used in the policy.
Transparency when involving health care professionals and patients in the process of policy elaboration is essential to guarantee compliance. The media should be seen as an alliance, so information given must also be transparent and retrieved from confident sources (Gazmararian et al., 2006; Ringel et al., 2009) .
Ethics
Policy implementation is certainly enhanced when decision makers are perceived to act in a responsible and ethical manner. Healthcare professionals have rights and obligations that must be taken into account, but during a pandemic the individual rights are questionable in the benefit of the society. This polemic statement is discussed in some of the articles included, and contradictory opinions are given (Dupras and Williams-Jones, 2012; Monto et al., 2011) .
Implications
This literature review did not retrieve any publication conducted in France that evaluated the decision process regarding influenza policy with policy makers involved. Few studies conducted in the US and Canada reported findings obtained after surveys or workshops promoted with the objective of improving the seasonal influenza plan and the preparedness plan for pandemic influenza. According to these studies, feedbacks of the workshops were positive and changes were successfully approved and adopted by local vaccination policies.
However, studies surveying patients and healthcare professional against vaccination were not found (Doxtator et al., 2004; Neudorf et al., 2003; Oxford et al., 2005; Stroud et al., 2011) .
CONCLUSION
Articles included in this literature review were retrieved since the 1990s until 2012. Most of them were conducted in the North America (59%) and Europe (11%). Stakeholders were identified as institutional, production and consumers levels. Decisions were made in both seasonal and pandemic context regarding several levels of the vaccine lifecycle chain. Each step of this chain required specific decisions, which were based on similar evidence in different countries. However, no standard process among locations was observed. External factors, such as the health system, economic context and the resources allocated influenced on the decision making process.
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Further studies based on this literature review will consist on the elaboration of questionnaires and a semi-structured interview. These could be applied to the stakeholders involved in the vaccination policy here identified, for example by comparing different locations or levels of decisions, and groups pro and against vaccination. Evidences and information used may be stated to the respondents, for verifying the existence of standard procedures or justifying such a position regarding vaccination. Local peculiarities of French health system, the political and economic context and in case of a pandemic or not must be taken into account. After validation and data collection in France a second phase is planned.
Questionnaires and the interview could be adapted to stakeholders located in the Netherlands. 
